Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the treatment effect in patients with upper gastro-intestinal complaints with an elevated risk for NSAID-associated GI-damage to those without an elevated risk for NSAID-associated damage (as determined by the treating physician).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Inclusion Criteria:
Patient with upper gastro-intestinal complaints (defined as heartburn and/or regurgitation and/or nausea and/or bloated feeling)and treatment with esomeprazole 20mg once daily is started because of this (consult 1). Upper gastro-intestinal complaints are thought to be related to NSAID use
Patient is using an NSAID** with the following conditions:
(**)OTC or Prescription NSAID
(**)Conventional NSAID or COX-2 selective NSAID
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients presenting at general practitioner
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andrea Sellink | AstraZeneca | Study Director |
| N van den Berk | AstraZeneca | Study Chair |
Not provided
| ID | Term |
|---|---|
| D006356 | Heartburn |
| D005764 | Gastroesophageal Reflux |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D015154 | Esophageal Motility Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D003680 | Deglutition Disorders |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |